BioCentury

7:00 AM GMT, Apr 16, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Adolor chronicles

Adolor chronicles

After hitting a six-year high last September, Adolor (ADLR) began a steady descent when it and partner GlaxoSmithKline (LSE:GSK; GSK) reported mixed Phase III data on their Entereg bowel dysfunction candidate. ADLR took another hit in November when it received a second approvable letter for Entereg asking for 12-month safety data. Those data came out

Read the full 564 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.